Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.
PMID 40981426 · PMC12877753 · Cancer discovery · 2026 · 8 claims · 7 setups
FOLFIRI-resistant PDX tumors show transcriptional upregulation of innate immunity and mitochondrial metabolism genes and reduced expression of DNA polymerase POLD1
-
Full-text index only
Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancer.
PMID 41630032 · PMC13037280 · Journal of experimental & clinical cancer research : CR · 2026 · 8 claims · 8 setups
Four isogenic carboplatin-resistant (CR) PDX pairs (WHIM30, BCM-2147, BCM-3887, BCM-7482) were generated via serial in vivo carboplatin exposure to model acquired resistance in TNBC
-
Full-text index only
Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor.
PMID 41850280 · PMC13103949 · Cell reports · 2026 · 8 claims · 8 setups
Chemotherapy-resistant KT-47R tumors show blastemal predominance and reduced stromal content compared to pre-treatment KT-47PT
-
Full-text index only
Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia.
PMID 41270153 · PMC7618455 · Cancer research · 2026 · 8 claims · 8 setups
ReSisTrace single-cell lineage tracing identifies pre-resistant and pre-sensitive cell states to FLT3 inhibitors midostaurin and quizartinib in FLT3-ITD-positive MOLM-13 AML cells before treatment
-
Full-text index only
Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.
PMID 41842971 · PMC13132380 · The Journal of clinical investigation · 2026 · 8 claims · 8 setups
PRC2i/EZH2i alone or combined with AR inhibitors induce diverse cell state programs (CSPs) that increase tumor cell invasion, metastasis, and drug resistance despite only modest suppression of tumor growth.